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INTRODUCTION
Human plasminogen (PLG), a key proenzyme in the fib-
rinolytic and thrombolytic systems, is a single chain glyco-
protein with a molecular mass of about 93 kDa and consists
of 791 amino acid residues (1). Congenital plasminogen defi-
ciency has been classified into two types. In type I, the con-
centration of immunoreactive PLG is reduced in parallel
with functional activity and in type II (dysplasminogenemia,
dysPLGemia), the level of immunoreactive protein is normal,
while the functional activity is reduced (2). Congenital defi-
ciency of PLG and dysPLGemia have been reported in asso-
ciation with venous thrombosis that develop in patients at
relatively young age (3, 4). Human PLG gene spans about
52.5 kb on chromosome 6q26-27 and consists of 19 exons
separated by 18 introns (5).
Aoki et al. (6) investigated a patient with recurring throm-
bosis and the only abnormality was depressed PLG in plas-
ma. Miyata et al. (7) referred to the abnormal PLG as PLG
Tochigi and showed that the abnormality is replacement of
alanine by threonine (Ala601Thr) due to the nucleotide change
of G to A transition in codon 601 of exon XV. Two other types
of point mutations (Val355Phe, Asp676Asn) in the PLG
gene have been described in patients with dysPLGemia (8).
In this study, we measured the PLG activity in patients
with deep vein thrombosis and analyzed the DNA sequence
to detect three point mutations (Ala601Thr, Val355Phe, and




Citrated venous blood was drawn from 57 normal indi-
viduals (29 males and 28 females, age; mean±SD, 50±18
yr) as well as 36 patients (21 males and 15 females, age; mean
±SD, 51±16 yr) with deep vein thrombosis. The diagnosis
of deep vein thrombosis was made by history, physical exami-
nation, and diagnostic studies including venogram and ultra-
sonography. One patient was complicated with pulmonary
embolism and three patients suffered from recurrent deep
vein thrombosis, renal vein thrombosis, and underlying lym-
phoma, respectively. Plasma samples were obtained by cen-
trifugation and aliquots were stored at -70℃ until analysis.
Genomic DNA samples were prepared from leukocytes by
the standard technique.
Plasminogen assay
The PLG activity was determined by amidolytic assay using
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Detection of an Ala601Thr Mutation of Plasminogen Gene in 3 out of 
36 Korean Patients with Deep Vein Thrombosis
Plasminogen is a key proenzyme in the fibrinolytic and thrombolytic systems. Con-
genital deficiency of plasminogen and molecular abnormality of plasminogen (dys-
plasminogenemia) have been reported in association with the thrombotic tendency
in human. In dysplasminogenemia, the level of immunoreactive plasminogen is
normal, although the functional activity is reduced. Human plasminogen gene
spans about 52.5 kb of DNA and consists of 19 exons. Three types of mutations
(Ala601Thr, Val355Phe, and Asp676Asn) have been described in dysplasmino-
genemia. In this study, we measured the plasminogen activity in patients with
deep vein thrombosis and analyzed the DNA sequence to detect three point
mutations (Ala601Thr, Val355Phe and Asp676Asn) in patients with hypo/dys-
plasminogenemia. Dysplasminogenemia was identified in 3 (8.3%) of unrelated
36 patients with deep vein thrombosis and the Ala601Thr mutation was detected
in all three patients with dysplasminogenemia. In conclusion, dysplasminogene-
mia is not rare in deep vein thrombosis, which suggests a risk factor for the throm-
bosis in Korean population.
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automatic coagulyzer (STA) and reagent kits (Stachrom PLG,
Diagnostica Stago, France). The plasminogen antigen concen-
tration was measured by immunoturbidimetric assay using
Behring Coagulation System (Dade Behring, U.S.A.).
PCR Amplification and Sequence Analysis
Genomic DNA was amplified by employing 3 sets of
primers (Exon X; 5′ -GTCAGAATTATTCTCAGAGGCT-
ACCGTACT-3′ and 5′ -CTACGAATTCTGGGTCTAAG-
AGAAATTTGG-3′ , Exon XV; 5′ -TCTGGAATTCTGT-
ACAATGGAGCAGAACAAA-3′ and 5′ -CCACGAATT-
CATCTGTACTGTGTCTTTCTTCT-3′ , Exon XVII; 5′ -
TGAAAGCTTGTGGGTACTGCAGCTGC-3′ and 5′ -A-
CCGAATTCATGGATAGGAATTTGCACAGC-3) in a
50  L reaction mixture as previously described (4). DNA
sequence was obtained using ABI PRISM 3700 DNA ana-
lyzer (Applied Biosystems, Foster City, CA, U.S.A.).
RESULTS
Plasma activities and antigen levels of plasminogen
Table 1 shows the results of plasma PLG activity in normal
subjects (n=57) and patients (n=36) with deep vein throm-
bosis. The mean (±SD) activity of PLG in normal subjects
was 103% (±11%) with a range from 78% to 129%.  The
mean (±SD) activity of PLG in patients with deep vein
thrombosis was 97% (±22%) with a range from 38% to
139%. Four (11.1%) of 36 patients had reduced PLG activi-
ties. Three (75%) of 4 patients with reduced plasminogen
activities had normal antigenic plasma concentrations as
shown in Table 2. Therefore, these three (8.3%) cases were
consistent with the diagnosis of dysPLGemia.
Genetic analysis 
To identify 3 point mutations (Ala601Thr, Val355Phe, and
Asp676Asn) in the regions mentioned above, genomic DNAs
were sequenced in four patients with hypo/dysPLGemia. In
three patients with dysPLGemia, nucleotide sequence analy-
sis revealed a heterozygous G to A transition (Ala601Thr
mutation) in exon XV (Fig. 1). The Ala601Thr mutation
was not detected in one patient with low PLG activity and
reduced antigen, whose diagnosis was consistent with hypo-
PLGemia. Two other mutations (Val355Phe and Asp676Asn)
were not identified in any of the four patients with hypo/dys-
PLGemia.
DISCUSSION
Although venous thrombosis often appear to be sponta-
neous in origin, it is associated with one or more predispos-
ing factors in the great majority of instances. Some common
situations are venous stasis, endothelial injury, and circulat-
ing activated clotting factors (9). Less often, hereditary or
acquired defects of the natural anticoagulants or fibrinolytic
defects are involved (10). In this study, fibrinolytic defect
due to hypo/dysPLGemia was identified in about 10% of
unrelated patients with deep vein thrombosis and heterozy-
gous Ala601Thr mutations were detected in all the patients
with dysPLGemia.
Partial human PLG deficiency was first described in a 31
yr-old male patient with a history of repeated episodes of
thrombophlebitis, intracranial and mesenteric venous throm-
bosis, and pulmonary embolism (6). Reduced PLG (50% of
normal) in his plasma was traced to a codon 601 missense
mutation in exon XV (GCT for Ala�ACT for Thr) (7), and
several additional patients with this defect have now been
described (3).
Previously, by isoelectric focusing electrophoresis, several
workers identified a functionally inactive PLG variant des-
ignated PLG M5, and demonstrated that PLG Tochigi and
PLG Nagoya II are identical and has a feature common to
PLG M5 with an Ala601Thr point mutation (11).
The Ala601Thr mutation is thought to be relatively preva-
lent and the gene frequency (0.02) is significantly higher
among normal Japanese than in other populations (12). Tsut-
sumi et al. (4) detected an Ala601Thr mutation in 118 (94%)
out of 125 unrelated Japanese families with dysPLGemia.
Therefore, it was likely that the frequency of the Ala601Thr
mutation is high because of the so-called founder’s effect (13).
It is noteworthy that the Ala601Thr mutation has been found
in the Chinese Han population (14). The G to A nucleotide
change in the codon 601 of exon XV may be a “hot spot” for
mutation, or alternatively, Japanese, Chinese, and Korean
families with dysPLGemia may share a single ancestor with
DVT    36      97±22 38-139
Normal        57 103±11 78-129
Group No.
Table 1. Plasma activity of plasminogen in the patients with
deep vein thrombosis (DVT) and in normal subjects
Plasminogen  Activity (%)
Mean±SD Range
1  62         M 69 10.0
2  56         F 55 16.8
3  52         M 67 14.4
4  49         F 38  3.8




Table 2. Plasma activities and antigen levels of plasminogen
in four patients with hypo/dysplasminogenemia
Plasminogen
Activity (%) Antigen (mg/dL)Ala601Thr Mutation of Plasminogen Gene in Deep Vein Thrombosis 169
the Ala601Thr mutation. At any rate, our study suggests
that this mutation is not as rare as had been thought in Korean
population. Therefore, it may be worth including the deter-
mination of plasma PLG activity and this type of mutation
in the screening test for genetic defects of inherited throm-
bophilia.
In a study of a Japanese cohort, approximately 27% of
individuals with dysPLGemia had a clinical history of throm-
bosis (4). Although the role of PLG deficiency in the patho-
genesis of venous thromboembolism is debated in the liter-
ature (15), several groups clearly favor the association between
PLG deficiency and thrombosis (16-19). Moreover, structural
studies on a hereditarily abnormal PLG, PLG Tochigi have
shown that Ala601 (equivalent to Ala55 in the chymotrypsin
numbering system) is very near the active site His57. The
Thr at position 55 in PLG may perturb His57 such that the
proton transfers associated with the normal catalytic process
cannot occur in the abnormal plasmin (7).
The Val355Phe mutation was found in four unrelated
Japanese families, indicating that it is a recurring mutation
and is not very rare in Japan (4). However, Val355Phe as
well as a third mutation Asp676Asn was not found in any
of the four cases of hypo/dysPLGemia in this study, indicat-
ing these mutations are not as common as Ala601Thr muta-
tion. Ser572Pro and Gly732Arg mutations were also reported
in dysPLGemia (4, 20).
One of our cases (malignant lymphoma patient) without
Ala601Thr mutation is consistent with hypoPLGemia because
both the activity and antigenic concentration of PLG are
reduced. Acquired PLG deficiency, as may occur in liver dis-
ease, sepsis, and Argentine hemorrhagic fever due to decreased
synthesis and/or increased catabolism, has been frequently
associated with thrombotic vascular occlusion (21). In this
case, other natural anticoagulants such as antithrombin, pro-
tein C, and protein S were also found to be decreased, sug-
gesting an acquired condition possibly due to increased cata-
bolism or decreased synthesis. Hereditary hypoPLGemia
seems to be rare because only five cases among 164 individ-
uals were classified into hypoPLGemia in Japanese popula-
tion (4).
The limitation of this study is that the evaluation for the
PLG levels and genetic study were not conducted in the fami-
ly members of our four cases.
Further studies on both symptomatic and asymptomatic
family members are required to confirm the relationship of
dysPLGemia with Ala601Thr mutation and thrombosis.
Fig. 1. The results of nucleotide sequencing analysis from three patients with dysplasminogenemia (A, B, C) and a patient with hypo-
plasminogenemia (D). Nucleotide sequence analysis revealed a heterozygous G to A transition (GCT�ACT: Ala601Thr mutation) in
exon XV (A-C).
Val Leu Thr Ala  Ala His Cys
Thr
G T G TTG A C TNC T G CCC A C T G C
Val Leu Thr Ala  Ala His Cys
Thr
G T G TTG A C T G C T G CC CA C T G C
Val Leu Thr Ala  Ala His Cys
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